Quick Answer
BridgeBio Pharma, Inc. reported Total Revenue of $502.08 million for fiscal year 2025.
BridgeBio Pharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $502.08M +126.3% |
$221.90M +2285.3% |
$9.30M -88.0% |
$77.65M +11.4% |
$69.72M +745.1% |
$8.25M -79.7% |
| Revenue (ASC 606) | $502.08M +126.3% |
$221.90M +2285.3% |
$9.30M -88.0% |
$77.65M +11.4% |
$69.72M +745.1% |
$8.25M -79.7% |
| Diluted EPS | -$3.78 -31.2% |
-$2.88 +27.1% |
-$3.95 -21.2% |
-$3.26 +16.4% |
-$3.90 -2.6% |
-$3.80 |
| Total Assets | $936.02M +1.8% |
$919.34M +68.3% |
$546.38M -12.3% |
$623.04M -38.5% |
$1.01B +43.9% |
$703.59M +11.4% |
| Cash and Equivalents | $570.12M -16.3% |
$681.10M +81.2% |
$375.94M -0.2% |
$376.69M -4.3% |
$393.77M +10.6% |
$356.08M -2.1% |
| Long-Term Debt | — | $437.34M -2.0% |
$446.44M +3.6% |
$430.99M +0.1% |
$430.75M +366.1% |
$92.42M +0.7% |
| Stockholders Equity | -$2.09B -42.1% |
-$1.47B -8.4% |
-$1.35B -7.9% |
-$1.25B -44.1% |
-$870.41M -1603.1% |
$57.91M -85.8% |
| R&D Expense | $451.95M -10.8% |
$506.46M +11.1% |
$455.71M +14.1% |
$399.46M -11.4% |
$451.02M +33.8% |
$337.05M +60.5% |
| Operating Income | -$523.41M +11.7% |
-$592.97M +2.4% |
-$607.37M -18.6% |
-$512.20M +11.2% |
-$576.63M -21.5% |
-$474.48M -78.2% |
| Shares Outstanding | 194.77M +2.5% |
190.04M +8.5% |
175.08M +16.2% |
150.63M +2.2% |
147.34M +19.9% |
122.85M -0.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $120.70M | +4318.0% | +9.2% |
| Revenue (ASC 606) | September 30, 2025 | $120.70M | +4318.0% | +9.2% |
| Net Income | June 30, 2019 | -$69.0K | — | — |
| Diluted EPS | September 30, 2025 | -$0.95 | -10.5% | +0.0% |
| Total Assets | September 30, 2025 | $998.25M | +50.1% | -7.6% |
| Cash and Equivalents | September 30, 2025 | $642.95M | +141.4% | -14.2% |
| Long-Term Debt | June 30, 2025 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | -$1.93B | -57.2% | -8.1% |
| R&D Expense | September 30, 2025 | $112.87M | -6.3% | +1.5% |
| Operating Income | September 30, 2025 | -$145.20M | +24.3% | -8.1% |
| Shares Outstanding | September 30, 2025 | 192.63M | +1.9% | +0.8% |
- BridgeBio Pharma, Inc. reported Total Revenue of $502.08 million for fiscal year 2025.
- BridgeBio Pharma, Inc. showed an increase of +126.3% in Total Revenue compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported Revenue (ASC 606) of $502.08 million for fiscal year 2025.
- BridgeBio Pharma, Inc. showed an increase of +126.3% in Revenue (ASC 606) compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported Diluted EPS of $3.78 per share (loss) for fiscal year 2025.
- BridgeBio Pharma, Inc. showed a decrease of -31.2% in Diluted EPS compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported Total Assets of $936.02 million for fiscal year 2025.
- BridgeBio Pharma, Inc. showed an increase of +1.8% in Total Assets compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported Cash and Equivalents of $570.12 million for fiscal year 2025.
- BridgeBio Pharma, Inc. showed a decrease of -16.3% in Cash and Equivalents compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported Long-Term Debt of $437.34 million for fiscal year 2024.
- BridgeBio Pharma, Inc. showed a decrease of -2.0% in Long-Term Debt compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported Stockholders Equity of -$2.09 billion for fiscal year 2025.
- BridgeBio Pharma, Inc. showed a decrease of -42.1% in Stockholders Equity compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported R&D Expense of $451.95 million for fiscal year 2025.
- BridgeBio Pharma, Inc. showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported Operating Income of -$523.41 million for fiscal year 2025.
- BridgeBio Pharma, Inc. showed an increase of +11.7% in Operating Income compared to the prior fiscal year.
- BridgeBio Pharma, Inc. reported Shares Outstanding of 194.77 million shares for fiscal year 2025.
- BridgeBio Pharma, Inc. showed an increase of +2.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: